On this page
Dupuytren contracture
This condition leads to gradual thickening and tightening of tissue beneath the skin of the palm and fingers, creating nodules and cords that pull the fingers into a bent position. It predominantly affects people of Northern European ancestry and becomes more common with age.
Overview
Dupuytren contracture develops when the palmar fascia - a layer of connective tissue beneath the skin of the hand - undergoes abnormal thickening and contracture. Initially, small firm nodules appear in the palm, typically near the base of the ring or little finger. Over months to years, these nodules may develop into thick cord-like bands that gradually pull the affected fingers towards the palm, making it difficult or impossible to fully straighten them.
The condition typically progresses slowly and affects around 3-6% of people of Northern European descent, though prevalence varies considerably with age and ancestry. Men are affected more frequently than women, and onset usually occurs after age 40, with prevalence increasing substantially in later decades. Whilst the condition itself is not life-threatening, progressive contracture can significantly impact hand function and quality of life.
Symptoms & clinical features
The earliest sign is often a small, firm nodule or lump in the palm, usually at the base of the ring finger or little finger. These nodules may initially be tender but typically become painless over time. As the condition progresses, rope-like cords of thickened tissue develop beneath the skin, extending from the palm into one or more fingers.
Gradually, these cords contract and pull the affected fingers into a bent position towards the palm. The ring finger and little finger are most commonly affected, though the middle finger can be involved, and the thumb and index finger are rarely affected. In advanced cases, the contracture can become severe enough that the fingertip touches the palm. Unlike trigger finger, the affected digits in Dupuytren contracture cannot be passively straightened without treatment. Some individuals may also develop thickened tissue on the soles of the feet (plantar fibromatosis) or firm nodules on the knuckles (Garrod pads), though these associated features do not always occur together.
Video: Genetics 101
Affected organs
Dupuytren contracture primarily affects the hands, specifically the palmar fascia - the sheet of fibrous tissue that lies between the skin and the tendons of the palm. This tissue normally helps anchor the skin and provide grip strength. The fourth and fifth rays (ring and little fingers) are most commonly involved, though any finger can be affected.
Whilst the hands are the primary site, some individuals develop related fibroproliferative changes in other anatomical locations. These may include plantar fibromatosis (Ledderhose disease) affecting the sole of the foot, or penile fibromatosis (Peyronie disease). When these conditions occur together with Dupuytren contracture, they are sometimes referred to as Dupuytren diathesis, though the relationship between these manifestations is not fully understood.
Risks & severity
Severity varies considerably between individuals. Some people develop only minor nodules that remain stable for years without significant functional impairment. Others experience progressive contracture that substantially limits hand function, affecting daily activities such as gripping objects, washing the face, or wearing gloves. The rate of progression is unpredictable and may include periods of stability alternating with phases of relatively rapid advancement.
Certain features are associated with more aggressive disease. Earlier age of onset (before age 50), bilateral hand involvement, family history, and the presence of associated conditions such as plantar or penile fibromatosis suggest a higher likelihood of progressive contracture. Northern European ancestry, male sex, diabetes, smoking, and alcohol consumption have been identified as risk factors, though the mechanisms underlying these associations remain incompletely characterised. Even after treatment, recurrence rates can be substantial, particularly in individuals with aggressive disease features.
Genetic causes
The underlying causes of Dupuytren contracture involve complex interactions between multiple genetic and environmental factors. Research suggests the condition has a polygenic basis, meaning numerous genetic variants across the genome each contribute a small effect towards overall risk. Family aggregation studies indicate that having an affected first-degree relative increases risk approximately threefold, and twin studies support a substantial heritable component.
Genome-wide association studies have identified several chromosomal regions associated with increased susceptibility, though no single causative gene has been established. The pathological changes involve abnormal proliferation of myofibroblasts - specialised cells that produce excessive collagen and contract the surrounding tissue matrix. This process shares some biological features with wound healing and scar formation, but the triggers that initiate and sustain this abnormal fibroproliferation in Dupuytren contracture are not fully understood. Environmental factors such as manual labour, hand trauma, smoking, and metabolic conditions likely interact with genetic predisposition to influence disease development and progression.
Inheritance pattern
Dupuytren contracture does not follow a simple Mendelian inheritance pattern. Instead, it demonstrates complex inheritance involving multiple genetic variants alongside environmental influences. The condition does tend to run in families - individuals with an affected parent or sibling have a notably increased risk compared to the general population - but predicting who will develop the condition based on family history alone is not straightforward.
Because numerous genes each contribute small effects, and because environmental factors also play a role, inheritance patterns within families can appear variable. Some family members may be severely affected whilst others remain unaffected or develop only mild changes. This polygenic architecture means that standard genetic testing to predict individual risk is not currently part of routine clinical practice for Dupuytren contracture. Family members concerned about their risk may wish to discuss this with their GP, particularly if they notice early nodules or have other risk factors.
Diagnosis & testing
Diagnosis is typically made through clinical examination by a GP, hand surgeon, or orthopaedic specialist. The characteristic nodules and cords in the palm, combined with progressive finger contracture, are usually sufficient for diagnosis without additional testing. The clinician will assess the degree of contracture, typically by measuring the angle between the finger and the palm when attempting to flatten the hand on a table surface.
Genetic testing is not routinely used in diagnosing Dupuytren contracture, as the condition's complex polygenic basis means that no single gene test can confirm or exclude the diagnosis. Imaging such as ultrasound or MRI is occasionally employed in research settings or to assess disease extent prior to treatment, but is not necessary for routine diagnosis. Referral to hand surgery services through the NHS typically occurs when contracture begins to interfere with hand function or when the degree of contracture reaches specific thresholds (commonly when the patient cannot place their hand flat on a table surface). There is no specific NHS R-code for genetic testing of Dupuytren contracture, reflecting its classification as a complex multifactorial condition rather than a monogenic disorder.
Management & lifestyle
Management depends on the degree of functional impairment and the rate of progression. Observation with regular monitoring is appropriate for mild cases that do not significantly affect daily activities. When contracture progresses to the point of functional limitation, several treatment options are available through the NHS, typically accessed via referral to hand surgery or orthopaedic services.
Treatment approaches include needle aponeurotomy (a minimally invasive procedure to divide the contracted cord), collagenase injection (an enzyme that breaks down the cord), and surgical fasciectomy (removal of the diseased tissue). Each approach has distinct advantages and recurrence rates, and the choice depends on individual factors including the degree and pattern of contracture, patient preference, and local expertise. Physiotherapy and hand therapy may support recovery following intervention. There is currently no established medical treatment to prevent progression, though research continues into potential disease-modifying approaches. Individuals are generally advised to avoid trauma to the hands where possible, and those with risk factors such as smoking may benefit from cessation support, though evidence that lifestyle modification alters disease course is limited.
UK care pathway
In the UK, individuals with Dupuytren contracture typically present first to their GP, who can provide initial assessment and advice. For mild disease without functional impairment, monitoring through primary care may be sufficient. When contracture progresses to cause functional limitation, GPs can refer to NHS hand surgery or orthopaedic services for specialist assessment and discussion of treatment options.
Because Dupuytren contracture is a complex multifactorial condition rather than a single-gene disorder, it does not feature in the NHS Genomic Medicine Service testing pathways, and referral to clinical genetics services is not part of the standard care pathway. PanelApp R-codes do not apply to this condition. Patients with questions about familial recurrence patterns or inheritance can discuss these with their hand surgeon or GP, though formal genetic counselling is not routinely indicated. The British Society for Surgery of the Hand provides resources and guidance on treatment standards across NHS services.
Frequently asked questions
Will my Dupuytren contracture definitely get worse over time?
Not necessarily. Progression is highly variable between individuals. Some people develop only small nodules that remain stable for years without causing problems, whilst others experience gradual worsening of contracture. Your hand specialist can assess your particular pattern and discuss whether monitoring or treatment is most appropriate at this stage.
Can anything prevent Dupuytren contracture from developing or progressing?
Currently, there is no proven way to prevent the condition from developing in those at risk, nor to reliably stop progression once it has started. Avoiding hand trauma and smoking cessation may be sensible, though evidence that these measures alter disease course is limited. Research into potential preventive treatments is ongoing.
If I have treatment, will the contracture come back?
Recurrence is possible with all current treatment approaches, though rates vary depending on the procedure used, the severity of disease, and individual factors. Your hand surgeon can discuss the recurrence rates associated with different treatment options and help you weigh the benefits and risks of intervention versus continued observation.
My parent had Dupuytren contracture - what are my chances of developing it?
Having an affected first-degree relative does increase your risk compared to the general population, but many people with a family history never develop the condition. Because multiple genetic and environmental factors are involved, it is not possible to predict individual risk precisely. If you notice nodules developing in your palm, discuss this with your GP.
References
- Anand P, Beutel BG, Rehman UH. Dupuytren Contracture. 2026. PMID: 30252330
- Davis TR. The enigma that is Dupuytren's contracture. The Journal of hand surgery, European volume. 2015. PMID: 25618866
- Townley WA, Baker R, Sheppard N. Dupuytren's contracture unfolded. BMJ (Clinical research ed.). 2006. PMID: 16484265
- Menoušek J, Šácha ZDT. Objective and subjective assessment of Dupuytren's contracture. Acta chirurgiae plasticae. 2023. PMID: 37722904
- Pearce RL. Dupuytren's contracture. The Medical journal of Australia. 1991. PMID: 1857310
- Dupuytren's contracture. Lancet (London, England). 1986. PMID: 2874334
- Dupuytren's contracture. British medical journal. 1976. PMID: 974566
- LANGSTON RG, BADRE EJ. Dupuytren's contracture. Canadian Medical Association journal. 1948. PMID: 18897546